Citius Oncology doubles share reserve to 30M under 2024 equity plan; issues 360K warrants

CITIUS ONCOLOGY, INC.

Board approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.
Issued warrants to purchase 360K shares of common stock at $2.1875, exercisable March 10, 2026, expiring 2031.
Warrants issued in private placement under Section 4(a)(2) to a financial advisor.
No other changes were made to the 2024 Plan besides the share increase.

item 3.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

CITIUS ONCOLOGY, INC. issued up to 360,000 shares of common stock of warrant to a financial advisor.

Security: warrant
Shares: up to 360,000 shares of common stock
Purchaser: a financial advisor

Exact text from the filing

On September 19, 2025, Citius Oncology, Inc. (the “Company) issued to a financial advisor warrants to purchase up to 360,000 shares of our common stock with an exercise price of $2.1875 per shares, that are exercisable on March 10, 2026, and that expire on March 10, 2031.

View on SEC.gov

Browse all equity issuances →

CITIUS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-089615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.